Patents Assigned to Avestha Gengraine Technologies Pvt. Ltd.
-
Patent number: 7994406Abstract: The present invention relates to the induction of the endogenous MnSOD expression in the chloroplast which scavenges reactive oxygen species in the plant cells and provides the means of cultivating crops in areas where it would not otherwise grow normally on account of environmental stress conditions inclusive of high and low temperatures, drought and ultra violet light, and resistance to herbicides so as to increase yield and improve crop quality.Type: GrantFiled: December 9, 2002Date of Patent: August 9, 2011Assignee: Avestha Gengraine Technologies Pvt. Ltd.Inventor: Villoo Morawala Patell
-
Publication number: 20090036356Abstract: The present invention is directed to novel Octanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of Octanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of Octanoic acid derivatives of the invention. The invention further relates to the kits and other articles of manufacture for treating disease states associated with DPP-IV enzyme.Type: ApplicationFiled: March 6, 2007Publication date: February 5, 2009Applicant: Avestha Gengraine Technologies Pvt. Ltd.Inventors: Villoo Morawala Patell, Akash Mathur, Amitesh Suman, V. Fredrick Devadoss
-
Publication number: 20080166432Abstract: The invention relates to extracts from Terminalia plant species that are capable of being used in methods for managing diseases such as cardiovascular disease, diabetes, degenerative neurological diseases, cancer, age related diseases like amyloidosis, acute pancreatitis, arthritis, atherosclerosis, cancer, heart diseases, inflammatory bowel disease, myocardial infarction, senile dementia, retinal degeneration and senile cataract; owing to the extracts antioxidation potential. The invention also relates to extracts from Terminalia plant species that are capable of being used in methods for managing various infectious diseases.Type: ApplicationFiled: August 15, 2003Publication date: July 10, 2008Applicant: Avestha Gengraine Technologies Pvt. Ltd.Inventors: Villoo Morawala Patell, Dhruvdev Vyas
-
Publication number: 20080051452Abstract: The present invention is directed to novel hexanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of hexanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of hexanoic acid derivatives of the invention. The invention further relates to the kits and other articles of manufacture for treating disease states associated with DPP-IV enzyme.Type: ApplicationFiled: March 6, 2007Publication date: February 28, 2008Applicant: Avestha Gengraine Technologies Pvt. Ltd.Inventors: Villoo Patell, Akash Mathur, Amitesh Suman, V. Fredrick Devadoss
-
Publication number: 20080020971Abstract: The present invention is directed to novel heptanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of heptanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of heptanoic acid derivatives of the invention. The invention further relates to the kits and other articles of manufacture for treating disease states associated with DPP-IV enzyme.Type: ApplicationFiled: March 6, 2007Publication date: January 24, 2008Applicant: Avestha Gengraine Technologies Pvt. Ltd.Inventors: Villoo Patell, Akash Mathur, Amitesh Suman, V. Fredrick Devadoss
-
Publication number: 20070270492Abstract: The present invention is directed to novel nananoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of nananoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of nananoic acid derivatives of the invention. The invention further relates to the kits and other articles of manufacture for treating disease states associated with DPP-IV enzyme.Type: ApplicationFiled: March 6, 2007Publication date: November 22, 2007Applicant: Avestha Gengraine Technologies Pvt. Ltd.Inventors: Villoo Patell, Akash Mathur, Amitesh Suman, V. Fredrick Devadoss
-
Publication number: 20070232573Abstract: The present invention is directed to novel Ethanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of Ethanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of Ethanoic acid derivatives of the invention. The invention further relates to the kits and other articles of manufacture for treating disease states associated with DPP-IV enzyme.Type: ApplicationFiled: March 6, 2007Publication date: October 4, 2007Applicant: Avestha Gengraine Technologies Pvt. Ltd.Inventors: Villoo Patell, Akash Mathur, Amitesh Suman, V. Fredrick Devadoss
-
Publication number: 20070006349Abstract: The present invention relates to the induction of the endogenous MnSOD expression in the Chloroplast which is ravages by reactive oxygen species ain one or more compartments of the plant cells and provides the means and wherewithal of cultivating crops in areas where it would not otherwise grow normally on account of environmental stress conditions inclusive of high and low temperatures, drought and ultra violet light, is resistant to herbicides thereby resulting in an increase in yield and also improved crop quality.Type: ApplicationFiled: December 9, 2002Publication date: January 4, 2007Applicant: Avestha Gengraine Technologies Pvt. Ltd.Inventor: Villoo Patell
-
Publication number: 20060269621Abstract: In this invention we have characterized plant extracts derived from common plants used in Indian traditional medicine using a) chemical fingerprinting by HPLC and b) etiology based in-vitro cell assays in order to reduce the extracts to minimum constituent to use for therapeutic purpose against degenerative conditions like cardiovascular diseases, Diabetes mellitus, Hypertension, All types of Cancers, Obesity & weight problems, Arthritis & pain, Alzheimer's disease, Multiple sclerosis & Autoimmune diseases, Asthma & Allergies, Osteoporosis & bone health, Parkinson's disease, Stress, Disorders & diseases of the eye. The current status of the extracts is that all of them have been chemically fingerprinted and have gone through assays to screen anti-diabetic activity. Thus currently we are applying for the specific leads that have shown very specific anti-diabetic activity.Type: ApplicationFiled: July 23, 2004Publication date: November 30, 2006Applicant: Avestha Gengraine Technologies Pvt.Ltd.Inventor: Villo Patell